STEPHEN DAVIS - 05 Apr 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role: CEO, Director
Signature: /s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol: ACAD
Transactions as of: 05 Apr 2023
Net transactions value: -$155,849
Form type: 4
Filing time: 07 Apr 2023, 20:34:55 UTC
Previous filing: 27 Feb 2023
Next filing: 02 May 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACAD	Common Stock	Options Exercise		+17,333	+19%		109,060	05 Apr 2023	Direct	F1
transaction	ACAD	Common Stock	Sale	$155,849	-8,582	-7.9%	$18.16	100,478	06 Apr 2023	Direct	F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACAD	Restricted Stock Units	Options Exercise	$0	-17,333	-25%	$0.000000	52,000	05 Apr 2023	Common Stock	17,333		Direct	F1, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
F2	The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.16 to $18.1752, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4	The restricted stock units vest in four equal annual installments beginning April 5, 2023.